Xifdinta Araggaaga (Eye Care)
Waxa muhiim ah baaritaano indhaha ah oo joogto ah, si looga hortago dhaawac aan loo baahnayn oo ka yimaadaa xaalado aan la cilad-sheegin. Waxa muhiim in la cilad-sheego goor hore ilmaha qaba dhibaato aragga ah si looga hortago dhibaatooyin waxbarasho iyo korniin.
Dadka sida gaarka ah inay u xifdiyeen indhahooda la rabo, waxaa ka mid ah:
• Ilmaha ka yar 16 sannadood,
• Dadka da’da yar ee ka yar 19 sannadood ee ku jira waxbarasho waqti buuxa ah,
• Dadka lagu sheegay guluukooma (glaucoma) ama cadaadis sare oo indhaha ah (ocular hypertension),
• Dadka ka weyn da’da 40 ee leh qaraabo soke oo lagu sheegay guluukooma (glaucoma),
• Dadka lagu sheegay sonkor ama kaadi-macaan,
• Dadka loo diiwaan galiyay arag bar ah ama indho la’aan,
Waxa kale oo jira dhawr siyaabood oo aad ku yareyn kartid waxyeelo indhaha soo gaara:
• Si joogto ah araggaaga ha loo baaro – ugu yaraan shantii sannadood mar. Haddii aad sonkor qabtid waa in araggaaga la baaraa in ka badan intaa.
• Indhahaaga ka ilaali qorraxda. Falaadhaha UV (ultra violet) ee qorraxdu waxay dhaawici karaan aragga indhahaaga sidaa daraadeed waxa muhiim ah inaad gashatid muraayado qorrax oo leh badbaadin UV oo sareysa marka aad u baxaysid dibad qorrax badan.
• Soo ogow haddii qoyskaagu taariikh u leeyahay guluukooma (glaucoma) ama cudur indhaha ah. Waa in araggaaga la baaro labadii sannadoodba mar haddii aad leedahay qaraabe soke oo lagu sheegay guluukooma (glaucoma).
• La soco isbeddelada xagga aragga indhahaaga. Sida ugu dhakhsaha badan ee suurogalka ah u tag Dhakhtarkaaga Guud (GP) haddii aad isku aragtid isbeddelo xagga aragga ah ama xanuun ah gudaha ama wareegga indhahaaga.
• Jooji sigaarka. Dadka sigaarka cabba ayaa saddex jeer uga badan dadka aan cabbin inay yeeshaan caad indhaha ku sameysma iyadoo sababtu tahay kiimikooyin laga helo qiiqa sigaarka.
W/D: Xiriirka Caafimaadka Soomaaliyeed
Short URL: http://www.caasimadda.com/?p=5770
Posted by Alaxmed
on Jul 22 2010. Filed under Caafimaadka, Maxaa Cusub?.
You can follow any responses to this entry through the RSS 2.0.
You can leave a response or trackback to this entry